Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 8/20 | 0.65 |
| ▸ | MAP4K4 | O95819 | 7/20 | 0.65 |
| ▸ | PRKD2 | Q9BZL6 | 6/20 | 0.65 |
| ▸ | EGFR | P00533 | 5/20 | 0.65 |
| ▸ | MAPK9 | P45984 | 4/20 | 0.65 |
| ▸ | MINK1 | Q8N4C8 | 4/20 | 0.65 |
| ▸ | PRKD3 | O94806 | 6/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | CLK2 | P49760 | 1/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.41 |
| ▸ | THRB | P10828 | 6/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.35 |
| ▸ | MARK3 | P27448 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4300827 | 0.84 | MAP4K4 (0.57) | CSNK1DMAP4K4PRKD2EGFRMAPK9 | |
| SCHEMBL4296505 | 0.82 | MAP4K4 (0.56) | CSNK1DMAP4K4PRKD2EGFRMAPK9 | |
| SCHEMBL9056922 | 0.79 | MAP4K4 (0.64) | CSNK1DMAP4K4PRKD2EGFRMAPK9 | |
| SCHEMBL4304066 | 0.79 | CSNK1D (1.00) | CSNK1DMAP4K4PRKD2EGFRMAPK9 | |
| SCHEMBL4300842 | 0.77 | MAP4K4 (0.64) | CSNK1DMAP4K4PRKD2EGFRMAPK9 | |
| SCHEMBL4302811 | 0.77 | MAP4K4 (0.59) | CSNK1DMAP4K4PRKD2EGFRMAPK9 | |
| SCHEMBL4303245 | 0.77 | MAP4K4 (0.57) | CSNK1DMAP4K4PRKD2EGFRMAPK9 | |
| SCHEMBL4303988 | 0.76 | CSNK1D (0.95) | CSNK1DMAP4K4PRKD2EGFRMAPK9 | |
| SCHEMBL8990765 | 0.76 | MAP4K4 (0.56) | CSNK1DMAP4K4PRKD2EGFRMAPK9 | |
| SCHEMBL4299756 | 0.76 | MAP4K4 (0.58) | CSNK1DMAP4K4PRKD2EGFRMAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086764-A1 | TGF-ß Inhibitors | MIDCAP FINANCIAL TRUST | 2018-03-29 | — | — | US | claimed |
| US-12227508-B2 | TGF-β inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-20230123591-A1 | TGF-ß INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-11466018-B2 | TGF-β inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| US-20210130361-A1 | TGF-ß INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-05-06 | — | — | US | disclosed |
| US-10822337-B2 | TGF-β inhibitorC | RIGEL PHARMACEUTICALS, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-20180086764-A1 | TGF-ß Inhibitors | MIDCAP FINANCIAL TRUST | 2018-03-29 | — | — | US | disclosed |
| US-8188083-B2 | Triazolopyridazines | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188083-B2 | Triazolopyridazines | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188083-B2 | Triazolopyridazines | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090270402-A1 | Novel triazolopyridazines | ABBVIE INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090270402-A1 | Novel triazolopyridazines | ABBVIE INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090270402-A1 | Novel triazolopyridazines | ABBVIE INC. | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270402-A1 | Novel triazolopyridazines | MAP3K5, MAP3K1, MAP3K2 | CSNK1D 173/4885MAP4K4 24/4885PRKD2 76/4885 |
| US-12227508-B2 | TGF-β inhibitors | TGFBR1, TGFBR2, TGFB1 | CSNK1D 829/4885MAP4K4 2507/4885PRKD2 3485/4885 |
| US-10822337-B2 | TGF-β inhibitorC | TGFBR1, TGFBR2, TGFB1 | CSNK1D 799/4885MAP4K4 2342/4885PRKD2 3871/4885 |
| US-11466018-B2 | TGF-β inhibitors | TGFBR1, TGFBR2, TGFB1 | CSNK1D 829/4885MAP4K4 2507/4885PRKD2 3485/4885 |
| US-20210130361-A1 | TGF-ß INHIBITORS | TGFBR1, TGFBR2, TGFB1 | CSNK1D 746/4885MAP4K4 2626/4885PRKD2 3527/4885 |
| US-20180086764-A1 | TGF-ß Inhibitors | TGFBR1, TGFBR2, TGFB1 | CSNK1D 746/4885MAP4K4 2626/4885PRKD2 3527/4885 |
| US-20230123591-A1 | TGF-ß INHIBITORS | TGFBR1, TGFBR2, TGFB1 | CSNK1D 746/4885MAP4K4 2626/4885PRKD2 3527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.